Patients taking GLP-1 receptor agonists for obesity had a 41% lower risk of obesity-related cancers as compared with patients treated with diet or exercise, a large propensity-matched cohort study showed.
Read more at: https://www.medpagetoday.com/hematologyoncology/othercancers/121659
Patients taking the drugs for obesity had a 41% lower risk of related cancers
